Reta - Research Peptide

Reta is a synthetic triple receptor agonist peptide targeting GIP, GLP-1, and glucagon receptors simultaneously. It represents the most advanced generation of incretin-based research compounds currently available, with a growing body of preclinical and clinical literature examining its role in metabolic regulation, energy homeostasis, and glucose signalling pathways.

Compound Details

• Molecular Weight: 4759.5 g/mol

• CAS Number: 2381089-83-2

• Purity: >99% (HPLC verified)

• Form: Lyophilised powder

• Available sizes: 5mg, 10mg, 15mg, 20mg, 30mg

Research Background

Academic and clinical studies have investigated reta involvement in multi-receptor incretin signalling, adipose tissue metabolism, and glucose homeostasis models. As a triple agonist, it has been studied for its simultaneous action across GIP, GLP-1, and glucagon receptor pathways — a mechanism that distinguishes it from earlier generation single and dual receptor compounds. Phase 3 clinical trials are currently underway examining its metabolic applications. All preclinical research has been conducted in controlled in vitro and animal model settings.

Storage & Handling

Once reconstituted, store at 4°C. For laboratory research use only.

Quality Assurance

Every batch of Reta supplied by Biomaxx is independently third-party tested and HPLC verified to confirm >99% purity. A Certificate of Analysis (CoA) is available upon request.

For research purposes only. Not for human consumption. Must be handled by qualified researchers in a controlled laboratory environment.